The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis

Publication date: June 2018
Source:International Immunopharmacology, Volume 59
Author(s): Yubo Ma, Xu Zhang, Mengmeng Wang, Qing Xia, Jiajia Yang, Meng Wu, Renfang Han, Mengya Chen, Xingxing Hu, Yaping Yuan, Rui Liu, Guangming Jiang, Guixia Pan, Yanfeng Zou, Shengqian Xu, Faming Pan
ObjectiveDickkopf-1 (DKK-1) is an endogenous inhibitor of canonical Wnt pathway that was implicated in the pathogenesis of rheumatoid arthritis (RA), but the serum levels of DKK-1 in RA were inconsistent among studies. Therefore, we conducted a meta-analysis to systematically evaluate the relationship between serum DKK-1 levels and RA.MethodsPubMed, Web of Science and Cochrane Library were comprehensively retrieved till 1 January 2018 for pertinent studies. The pooled standard mean differences (SMDs) of serum DKK-1 levels were calculated according to the random effects model.ResultsNine original studies containing 1305 RA patients and 504 healthy controls were included in the meta-analysis. The pooled SMD of serum DKK-1 between RA patients and healthy controls was 0.79 (95% CI = 0.11 to 1.48, Z = 2.28 and P = 0.023), indicating a significantly higher serum level of DKK-1 in RA patients.ConclusionSerum level of DKK-1 is elevated in patients with RA compared to healthy controls, suggesting an important role of DKK-1 in the pathogenesis and treatment of RA.



https://ift.tt/2GW20aO